Navigation Links
Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma

MONTREAL--(BUSINESS WIRE)--May 15, 2007 - Gemin X Biotechnologies Inc. announced today that a report published in the journal Blood demonstrated that its lead compound, obatoclax (GX15-070), induced cell death in vitro in Mantle Cell Lymphoma (MCL) cell lines and primary cells from 11 MCL patients. Obatoclax (GX15-070) is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.

The study, which appears in the May 15 print edition of Blood, is titled, "The BH3-mimetic GX15-070 synergizes with Bortezomib in Mantle Cell Lymphoma by enhancing Noxa-mediated activation of Bak." It was led by Patricia Perez-Galan et al., from the Hematopathology Unit, Department of Pathology, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.

According to the report, GX15-070 was active in cells bearing defective DNA damage sensor genes or cell cycle regulators. Additionally, the compound synergized with bortezomib (Velcade(R)), a proteasome inhibitor, such that MCL cells became sensitized to low doses of bortezomib. Bortezomib was shown to induce the pro-survival Bcl member, Mcl-1, which causes resistance to the drug. Inhibition of Mcl-1 by GX15-070, in contrast, overcame this resistance. This positive preclinical activity of GX15-070 led to an increased activation of the apoptotic pathway, while showing no significant cytotoxic effect in normal cells from healthy donors when used both alone and in combination with bortezomib.

"The results of this study show that a small molecule inhibitor, such as obatoclax (GX15-070) that modulates the Bcl-2 pathway, is a rational approach for the treatment of MCL," said Gordon Shore, Chief Scientific Officer of Gemin X. "Its ability to enhance the effects of bortezomib by overcomi ng resistance mediated by Mcl-1 also reveals the breadth of the compound's therapeutic potential. These findings suggest that Gemin X's obatoclax (GX15-070) in combination with bortezomib may prove to be an attractive new approach in the treatment of MCL, and further support our recent initiation of this combination in a Phase 1b trial in MCL."

Gemin X is currently conducting several clinical trials of obatoclax (GX15-070) in multiple cancer types as a combination therapy and as a single agent. In addition to the Phase 1b trial in MCL, Gemin X recently initiated a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. Obatoclax (GX15-070) is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, obatoclax (GX15-070) was well-tolerated and resulted in clinical and biological activity.

About Mantle Cell Lymphoma (MCL)

Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related cancers that affect the lymphatic system. Mantle cell lymphoma is an aggressive B-cell lymphoma that historically has been resistant to current standard chemotherapeutic approaches, making it a difficult cancer to treat. The median survival time is three years and the ten-year survival rate is only 5-10%.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 pro-survival proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately hel d and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com

Velcade(R) is a registered trademark of Millenium Pharmaceuticals.

Contact

MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
jgreenleaf@macbiocom.com
or
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
investor_relations@geminx.com


'"/>




Related medicine technology :

1. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
2. Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
4. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):